

## FACULTY DETAILS

I. Name: DR RAJESH BABU YARLAGADDA

II. Designation: Professor & HOD

III. Date of Joining: 01-10-2016

IV. Date of Birth: 08-04-1979

V. Email Id: yraj79@gmail.com

VI. Educational Qualification:

1. B. Pharm: Rajiv Gandhi University of Health Sciences, 2001

2. M. Pharm: Rajiv Gandhi University of Health Sciences, 2007

Specialization: Pharmaceutical Chemistry

3. Ph.D.: JNTUH, Hyderabad, 2016

Title of Ph.D. thesis: "Synthesis, Chemical Characterization of Novel Substituted Acridones and their Multidrug Resistance Reversal Studies in Cancer Cells"



VII. International Publications: 05

1. Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies. Deepak Reddy Gade, Amareswararao Makkapati, **Rajesh Babu Yarlagadda**, Godefridus J. Petersd, B.S. Sastry, V.V.S. Rajendra Prasad, **Computational Biology and Chemistry**, 74 (2018)63-75
2. New RP-HPLC Method Development and Validation for the Determination of Pazopanib Hydrochloride in Tablet Dosage Form. **Rajesh Babu Y**, Appala Raju N; **International Journal of Pharmaceutical Quality Assurance**; 2017; 8(1); 9-12.
3. Synthesis of nitric oxide donating acridone derivatives as cytotoxic agents in cancer. M. Amareswararao , **Y. R. Babu** , J. Himabindhu and V. V. S. Rajendra Prasad; **Der Pharma Chemica**, 2016, 8(4):391-398.

4. Design and Synthesis of Quinazolinone Tagged Acridones as Cytotoxic Agents and Their Effects on EGFR Tyrosine Kinase. **Yarlagadda Rajesh Babu**, Mantripragada Bhagavanraju, Gade Deepak Reddy, Godefridus J. Peters, and Velivela V. S. Rajendra Prasad **Arch. Pharm. Chem. Life Sci.** 2014, Vol.347 (624-634).
5. Molecular fragmentation of some novel cytotoxic dichloro Acridones by electrospray ionization tandem mass spectrometry. **Yarlagadda Rajesh Babu** and Mantripragada Bhagavanraju; **Der pharmacia Lettre.** 2014, 6 (3): (242-245).

#### **VIII. National Publications: 16**

1. Focused Screening Libraries of Lead Optimization. Ausaf Butool, Hafsa Hussaini, Juveria Nausheen, Mohd Mudabbir, Dr. Y. Rajesh, Dr. Anupama Koneru. **World Journal of Pharmacy and Pharmaceutical Sciences**, 2020, 9 (2), (705-714).
2. Synthesis and Chemical Characterization of Benzimidazole Fused Benzopyran Derivatives and evaluation of their Anti-Bacterial Potency. Rufaida Farheen, **Y. Rajesh Babu**; **Journal of Pharma Research**, 2019, 8 (3):88-93.
3. Synthesis and Chemical Characterization of Benzopyran Derivatives Fused to Pyrimidine Moiety. Bibi Fareesa Banu<sup>1</sup>, **Y. Rajesh Babu**, Ausaf Butool, Tuba Khan; **Research & Reviews: A Journal of Drug Formulation, Development and Production**, 2018 5(3):11-23.

4. Synthesis and Chemical Characterization of Novel Series of Heterocyclic Compounds Containing Nitrogen and Oxygen. Ausaf Butool, **Y. Rajesh**, Tuba Khan, Bibi Fareesa Banu; **Research & Reviews: A Journal of Drug Formulation, Development and Production**, 2018 5(3):24-40.
5. Synthesis and Chemical Characterization of Novel Series of Benzoxazinone Derivatives. Tuba Khan, **Y. Rajesh Babu**, Bibi Fareesa Banu, Ausaf Butool; **Research & Reviews: A Journal of Drug Formulation, Development and Production**, 2018 5(3):41-57.
6. Formulation and evaluation of dabigatran fast dissolving tablets by using polypladone xl-10 and primellose. Ausaf Butool, Bibi Fareesa Banu, Tuba Khan, Rufaida Farheen, Dr. **Y Rajesh**; *Int. J. of Pharmacy and Analytical Research Vol-7(3) 2018 [301-316]*
7. Synthesis and Chemical Characterization of Some Novel Benzopyrans and Their Biological Activity Studies. **Yarlagadda Rajesh babu**, **Der Pharma Chemica**, 2017, 9(5):117-121.
8. A Validated RP-HPLC Method for the Determination of 2-Chloroadenosine as Process Related Impurity in Regadenosen Parenteral Dosage Form, **Y Rajesh Babu**, VVSS Appala Raju, N Appala Raju; *Journal of Chemical and Pharmaceutical Research*, 2017, 9(7):55-61.
9. Development and Validation of a Stability Indicating RP-HPLC Method for the Determination of Imatinib Mesylate; **Y Rajesh Babu**, N Appala Raju, **International Journal of Current Pharmaceutical Review and Research**; 2017; 8 (1), 56-59.
10. Pharmacophore Modelling, Atom- and Field-based 3D QSAR Studies of Cytotoxic Acridones Derivatives. G. Deepak Reddy, **Y. Rajesh Babu**, B. S. Sastry and V. V. S. R. Prasad; **Der Pharma Chemica**, 2016, 8(5):147-155.

11. Multidrug Resistance Reversal Acridones: Pharmacophore Modeling and 3D QSAR Studies; M. Amareswararao, **Y. Rajesh Babu**, V.V.S. Rajendra Prasad, **JPR**, 2016, 10 (6), (450-453).
12. Design and synthesis of acridone-4-carboximide derivatives and their cytotoxic studies in cancer cells; M. Amareswararao, **Y. Rajesh Babu**, V.V.S. Rajendra Prasad, **JPR**, 2016, 10 (10), (628-634).
13. Design and synthesis of 2, 4-dichloro N<sup>10</sup>-substituted acridones as cytotoxic agents effective against sensitive and resistant cancer cell lines. **Y. Rajesh babu**, M. Bhagavanraju, V. Jagadeesh babu; **IJPPS**, 2013, Vol.5 Issue.4 (308-318)
14. Acridone derivatives in reversing multidrug resistant in cancer cells- where are we now? Srikanth Gurrallaa , **Y. Rajesh Babua** , M. Bhagavan Raju: **WJPR**, 2013, Vol.2, issue.2 (308-318).
15. Symmetrical coupling of 2-mercaptobenzimidazole derivatives and their anti-microbial activity. Srikanth Gurralla, **Y. Rajesh babu**, G.vijayabhaskara rao, B. Madhavi latha; **IJPPS**, 2011, 3(2), 217-220.
16. Synthesis of new thiazolidin-4-one substituted 1, 2, 4-Triazoles as Antimicrobial agents. Rajendra Prasad, V.V.S., Mayur, Y.C., **Babu, Y.R.**, Satish, N.K., Shanta Kumar, S.M. **Indian Journal of heterocyclic chemistry**, 2006, 16, (199-200).

**IX. National Conferences:**

<b>Sl.No</b>	<b>Title of the paper presented</b>	<b>Title of conference / Seminar</b>	<b>Date with Year</b>	<b>Organized by</b>
1	Multidrug Resistance Reversal Acridones: Pharmacophore Modeling and 3D QSAR Studies	Novel Explorative Approaches Trending in Pharmaceutical Sciences	26 <sup>th</sup> March,2015	VIPER in association with APTI
2	Design and Synthesis of acridone carboxamides as anticancer agents	India-Pharmacy of the world ( Role of Indian regulators and pharma industry)	23 <sup>rd</sup> to 25 <sup>th</sup> , January 2015	66 <sup>th</sup> IPC
3	Cytotoxic studies of novel quinazolinone linked acridones against sensitive and resistant cancer cell lines	CPER 2013	29-30 <sup>th</sup> November 2013	CPS, IST, JNTUH in association with AICTE
4	Quinazolinone linked acridones as potent EGFR inhibitors and their cytotoxic studies against sensitive and resistant cancer cell lines	Innovate-2013	3 <sup>rd</sup> &4 <sup>th</sup> September, 2013	Pullareddy institute of pharmacy in assoaciation with AICTE
5	Molecular fragmentation of some novel cytotoxic dichloro Acridones by electrospray ionization tandem mass spectrometry.	Advanced Techniques in experimental methodology	25 <sup>th</sup> & 26 <sup>th</sup> March, 2013	VIPER in association with DST
6	Synthesis of nitric oxide donating acridone derivatives as cytotoxic agents in cancer.	RIPE-2012	17-18 <sup>th</sup> August, 2012	CPS, IST, JNTUH in association with APTI
7	Drug design and drug discovery	Techpragna-09	13 <sup>th</sup> &14 <sup>th</sup> march 2009	Mallareddy group of Institutions

**X. International Conferences:**

<b>Sl.No</b>	<b>Title of the paper presented</b>	<b>Title of conference / Seminar</b>	<b>Date with Year</b>	<b>Organized by</b>
1	Design and synthesis of acridone-4-carboximide derivatives and their cytotoxic studies in cancer cells.	“International conference on the use of National Medicines Policy and Biostatistics in Pharmaceutical Sciences” Innovate-2016	28 <sup>th</sup> & 29 <sup>th</sup> September-2016	Pullareddy institute of pharmacy in association with ISPOR
2	Nitric Oxide Donating Acridone Carboxamide Derivatives as Reverters of Doxorubicin Resistance in MCF7/DX Cells	International Symposium on recent Advances in Medicinal Chemistry	8 <sup>th</sup> to 10 <sup>th</sup> September, 2014	NIPER, Mohali
3	Design and synthesis of Acridones as Anti MDR agents in cancer and their mechanistic studies	4 <sup>th</sup> Annual Indo-American Pharmaceutical Regulatory Symposium	18 <sup>th</sup> to 20 <sup>th</sup> October 2012	JNTUH, India and Northeastern University Boston, USA

**XI. Chairperson/Judges/Organizing committee**

Sl.No	Judge / Committee member	Title of conference / Seminar	Date with Year	Organized by
1	Registration Committee member	Advances, Challenges & Future Strategies in the Pharmaceutical Industry & Pharmaceutical care	1 <sup>st</sup> & 2 <sup>nd</sup> February, 2019	Sultan-UI-Uloom College of Pharmacy
2	Co-Convener	Continuing Education Program Sponsored by Pharmacy Council of India	10 <sup>th</sup> -12 <sup>th</sup> September, 2018	Sultan-UI-Uloom College of Pharmacy
3	Co-Convener	PHARMALIVE AND ESCAPDE	16 <sup>th</sup> Decmber,2017	Sultan-UI-Uloom College of Pharmacy
4	Evaluator for poster presentation	“Role of Nanotechnology in Herbal Medicine” and “Quality by Design”	18 <sup>th</sup> & 19 <sup>th</sup> August,2017	Sri Venkateswara College of Pharmacy in association with SERB, DST
5	Scientific Committee member	(Race to Optimize Antibiotic Usage For Better Therapeutic Outcomes) SYNCHROPHARMA-2017	4 <sup>th</sup> & 5 <sup>th</sup> March,2017	Sultan-UI-Uloom College of Pharmacy
6	Evaluator for poster presentation	‘India’s Nano Pharmaceutical Needs’-Challenges and Opportunities”	18 <sup>th</sup> March, 2016	VIPER in association with APTI
7	Evaluator for poster presentation	Innovative emerging approaches in drug discovery	2 <sup>nd</sup> & 3 <sup>rd</sup> March 2012	VIPER in association with DST





**XII. Workshops/FDP (Total number attended & List):**

<b>S.No</b>	<b>Title of the Program</b>	<b>Duration (From – to)</b>	<b>Organized by</b>
1	Chemoinformatics in drug discovery	14 <sup>th</sup> -16 <sup>th</sup> February-2019	Ecell2K18-19(IIT Kharagpur)
2	Computer Aided Drug Design (NPTEL)	06-08-2018 to 07-10-2018	NPTEL-AICTE Faculty Development Programme
3	Acquiring and improving the skills through pharmacy and biotechnology	06-02-2017 to 25-02-2017	JNTUH (UGC Sponsored Refresher Course)

**XIII. M. Pharm Projects (Total no. of projects): 17**

**XIV. Memberships:** Life Member of APTI